SCHEMBL1048797

SCHEMBL1048797

COc1c(CCN)ccc2c1OCO2

nearest known ligand 0.44

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 2/20 0.44
HTR2A P28223 3/20 0.43
HTR2C P28335 2/20 0.43
HTR2B P41595 2/20 0.43
POLB P06746 2/20 0.43
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
CYP1A2 P05177 2/20 0.38
CYP3A4 P08684 2/20 0.38
ALOX15 P16050 1/20 0.38
ALDH1A1 P00352 1/20 0.38
CYP19A1 P11511 1/20 0.37
NQO2 P16083 1/20 0.37
CYP2D6 P10635 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10430981 0.87 POLB (0.43) POLBMEN1KMT2ACYP1A2CYP3A4
Hydrochloric Acid SCHEMBL10430668 0.85 POLB (0.42) HTR2APOLBMEN1KMT2ACYP1A2
SCHEMBL24986410 0.81 POLB (0.44) POLBCYP1A2CYP3A4ALOX15ALDH1A1
SCHEMBL10430644 0.80 POLB (0.48) POLBKMT2ACYP1A2CYP3A4ALOX15
SCHEMBL2556563 0.78 TAAR1 (0.49) TAAR1
SCHEMBL10430650 0.77 HTR7 (0.45) HTR2APOLBMEN1KMT2ACYP1A2
SCHEMBL10690900 0.77 POLB (0.41) HTR2APOLBMEN1KMT2ACYP1A2
SCHEMBL28498699 0.77 POLB (0.46) TAAR1HTR2AHTR2CHTR2BPOLB
SCHEMBL20561907 0.76 AOC3 (0.46) TAAR1HTR2AHTR2CHTR2BPOLB
Hydrochloric Acid SCHEMBL10430671 0.76 HTR7 (0.44) HTR2APOLBMEN1KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265045-A1 PHENALKYLAMINES AND METHODS OF TREATING MOOD DISORDERS GILGAMESH PHARMACEUTICALS, INC. (US) 2023-08-24 US disclosed
US-20230265045-A1 PHENALKYLAMINES AND METHODS OF TREATING MOOD DISORDERS GILGAMESH PHARMACEUTICALS, INC. (US) 2023-08-24 US disclosed
WO-2022006186-A1 PHENALKYLAMINES AND METHODS OF TREATING MOOD DISORDERS GILGAMESH PHARMACEUTICALS, INC. (US) 2022-01-06 WO disclosed
EP-2318126-B1 WATER PURIFICATION MEMBRANES WITH IMPROVED FOULING RESISTANCE UNIV TEXAS (US) 2018-08-22 EP disclosed
US-8017050-B2 Water purification membranes with improved fouling resistance BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (US) 2011-09-13 US disclosed
EP-2318126-A2 WATER PURIFICATION MEMBRANES WITH IMPROVED FOULING RESISTANCE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2011-05-11 EP disclosed
WO-2011005258-A1 POLYMER DEPOSITION AND MODIFICATION OF MEMBRANES FOR FOULING RESISTANCE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2011-01-13 WO disclosed
US-20100059433-A1 POLYMER DEPOSITION AND MODIFICATION OF MEMBRANES FOR FOULING RESISTANCE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2010-03-11 US disclosed
US-20100051538-A1 WATER PURIFICATION MEMBRANES WITH IMPROVED FOULING RESISTANCE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2010-03-04 US disclosed
WO-2010006196-A2 WATER PURIFICATION MEMBRANES WITH IMPROVED FOULING RESISTANCE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2010-01-14 WO disclosed
US-5877278-A SOLID PHASE SYNTHESIS USING TWO SUBMONOMERS-AN ACYLATING AGENT, E.G. A HALOACETIC ACID, AND A PRIMARY AMINE; CYCLIZATION TO PRODUCE MIMETICS OF DRUGS; ELIMINATION OF THE NECESSITY OF PROTECTION GROUPS CHIRON CORPORATION (US) 1999-03-02 US disclosed
US-5831005-A ACYLATION, NUCLEOPHILIC DISPLACEMENT CYCLES CHIRON CORPORATION (US) 1998-11-03 US disclosed
EP-0789577-A4 SYNTHESIS OF N-SUBSTITUTED OLIGOMERS CHIRON CORP (US) 1998-07-22 EP disclosed
EP-0789577-A1 SYNTHESIS OF N-SUBSTITUTED OLIGOMERS CHIRON CORPORATION (US) 1997-08-20 EP disclosed
EP-0671928-A4 SYNTHESIS OF N-SUBSTITUTED OLIGOMERS. CHIRON CORP (US) 1997-04-23 EP disclosed
WO-1996040202-A1 SYNTHESIS OF N-SUBSTITUTED OLIGOMERS CHIRON CORPORATION (US) 1996-12-19 WO disclosed
US-5480871-A TREATMENT OF BENIGN PROSTATIC HYPERPLASIA CHIRON CORPORATION (US) 1996-01-02 US disclosed
EP-0671928-A1 SYNTHESIS OF N-SUBSTITUTED OLIGOMERS CHIRON CORPORATION (US) 1995-09-20 EP disclosed
US-5447916-A Hypotensive agents CHIRON CORPORATION (US) 1995-09-05 US disclosed
WO-1994006451-A1 SYNTHESIS OF N-SUBSTITUTED OLIGOMERS CHIRON CORPORATION (US) 1994-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265045-A1 PHENALKYLAMINES AND METHODS OF TREATING MOOD DISORDERS PNMT, HTR2C, HTR2A TAAR1 66/4885HTR2A 3/4885HTR2C 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.